IDEAYA Biosciences, Inc. (IDYA): R&D Expense
$314.70M
Year ended 2025-12-31
$374.01M
Trailing 12 months to 2026-06-30
+52.0%
3-year compound annual growth
+51.3%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $314.70M | +6.8% | 2026-02-17, From 2025-01-01 |
| 2024-12-31 | $294.67M | +127.5% | 2026-02-17, From 2024-01-01 |
| 2023-12-31 | $129.51M | +44.6% | 2026-02-17, From 2023-01-01 |
| 2022-12-31 | $89.54M | +54.0% | 2025-02-18, From 2022-01-01 |
| 2021-12-31 | $58.16M | +46.5% | 2024-02-20, From 2021-01-01 |
| 2020-12-31 | $39.70M | +15.7% | 2023-03-07, From 2020-01-01 |
| 2019-12-31 | $34.32M | +8.1% | 2022-03-18, From 2019-01-01 |
| 2018-12-31 | $31.75M | +156.4% | 2021-03-23, From 2018-01-01 |
| 2017-12-31 | $12.38M | n/a | 2020-03-24, From 2017-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | 2025-12-31 | $314.70M | +6.8% |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $109.27M | +46.8% |
| Amarin Corp PLC (AMRN) | 2025-12-31 | $19.81M | -5.1% |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $62.07M | +13.0% |
| Anaptysbio, Inc (ANAB) | 2025-12-31 | $135.97M | -17.0% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $62.36M | +65.6% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $129.64M | -25.3% |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | $523.00M | +16.7% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $167.34M | -29.7% |
Compare IDYA, VNDA, AMRN, PBYI side by side · Screen every company in Pharmaceutical Preparations ↗